These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 20561034

  • 1. Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit.
    Ladis V, Chouliaras G, Berdoukas V, Moraitis P, Zannikos K, Berdoussi E, Kattamis C.
    Eur J Haematol; 2010 Oct; 85(4):335-44. PubMed ID: 20561034
    [Abstract] [Full Text] [Related]

  • 2. Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials.
    Xia S, Zhang W, Huang L, Jiang H.
    PLoS One; 2013 Oct; 8(12):e82662. PubMed ID: 24376563
    [Abstract] [Full Text] [Related]

  • 3. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
    Totadri S, Bansal D, Bhatia P, Attri SV, Trehan A, Marwaha RK.
    Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
    Elalfy MS, Adly AM, Wali Y, Tony S, Samir A, Elhenawy YI.
    Eur J Haematol; 2015 Nov; 95(5):411-20. PubMed ID: 25600572
    [Abstract] [Full Text] [Related]

  • 5. Longitudinal prospective comparison of pancreatic iron by magnetic resonance in thalassemia patients transfusion-dependent since early childhood treated with combination deferiprone-desferrioxamine vs deferiprone or deferasirox monotherapy.
    Ricchi P, Meloni A, Pistoia L, Gamberini MR, Cuccia L, Allò M, Putti MC, Spasiano A, Rosso R, Cecinati V, Righi R, Renne S, Peritore G, Vallone A, Positano V, Quaia E, Cademartiri F, Pepe A.
    Blood Transfus; 2024 Jan; 22(1):75-85. PubMed ID: 37146300
    [Abstract] [Full Text] [Related]

  • 6. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
    Cassinerio E, Orofino N, Roghi A, Duca L, Poggiali E, Fraquelli M, Zanaboni L, Cappellini MD.
    Blood Cells Mol Dis; 2014 Sep; 53(3):164-7. PubMed ID: 24846580
    [Abstract] [Full Text] [Related]

  • 7. Therapeutic mechanism of combined oral chelation therapy to maximize efficacy of iron removal in transfusion-dependent thalassemia major - a pilot study.
    Lin CH, Chen X, Wu CC, Wu KH, Song TS, Weng TF, Hsieh YW, Peng CT.
    Expert Rev Hematol; 2019 Apr; 12(4):265-272. PubMed ID: 30920854
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis.
    Sridharan K, Sivaramakrishnan G.
    Expert Rev Clin Pharmacol; 2018 Jun; 11(6):641-650. PubMed ID: 29727586
    [Abstract] [Full Text] [Related]

  • 9. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
    Fisher SA, Brunskill SJ, Doree C, Gooding S, Chowdhury O, Roberts DJ.
    Cochrane Database Syst Rev; 2013 Aug 21; 2013(8):CD004450. PubMed ID: 23963793
    [Abstract] [Full Text] [Related]

  • 10. Cost-utility analysis of deferiprone for the treatment of β-thalassaemia patients with chronic iron overload: a UK perspective.
    Bentley A, Gillard S, Spino M, Connelly J, Tricta F.
    Pharmacoeconomics; 2013 Sep 21; 31(9):807-22. PubMed ID: 23868464
    [Abstract] [Full Text] [Related]

  • 11. Recent developments in iron chelation therapy.
    Cario H, Janka-Schaub G, Janssen G, Jarisch A, Strauss G, Kohne E.
    Klin Padiatr; 2007 Sep 21; 219(3):158-65. PubMed ID: 17525910
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN, Kontoghiorghes GJ.
    Drug Des Devel Ther; 2016 Sep 21; 10():465-81. PubMed ID: 26893541
    [Abstract] [Full Text] [Related]

  • 13. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia.
    Fortin PM, Fisher SA, Madgwick KV, Trivella M, Hopewell S, Doree C, Estcourt LJ.
    Cochrane Database Syst Rev; 2018 May 08; 5(5):CD012349. PubMed ID: 29737522
    [Abstract] [Full Text] [Related]

  • 14. Cardiac events and cardiac T2* in Egyptian children and young adults with beta-thalassemia major taking deferoxamine.
    Elalfy MS, Abdin IA, El Safy UR, Ibrahim AS, Ebeid FS, Salem DS.
    Hematol Oncol Stem Cell Ther; 2010 May 08; 3(4):174-8. PubMed ID: 21150236
    [Abstract] [Full Text] [Related]

  • 15. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
    Saliba AN, El Rassi F, Taher AT.
    Expert Rev Hematol; 2016 May 08; 9(2):151-68. PubMed ID: 26613264
    [Abstract] [Full Text] [Related]

  • 16. Incidence of ototoxicity in pediatric patients with transfusion-dependent thalassemia who are less well-chelated by mono- and combined therapy of iron chelating agents.
    Tanphaichitr A, Kusuwan T, Limviriyakul S, Atipas S, Pooliam J, Sangpraypan T, Tanphaichitr VS, Viprakasit V.
    Hemoglobin; 2014 May 08; 38(5):345-50. PubMed ID: 25051423
    [Abstract] [Full Text] [Related]

  • 17. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.
    Neufeld EJ.
    Blood; 2006 May 01; 107(9):3436-41. PubMed ID: 16627763
    [Abstract] [Full Text] [Related]

  • 18. Iron-chelating therapies in a transfusion-dependent thalassaemia population in Thailand: a cost-effectiveness study.
    Luangasanatip N, Chaiyakunapruk N, Upakdee N, Wong P.
    Clin Drug Investig; 2011 May 01; 31(7):493-505. PubMed ID: 21627338
    [Abstract] [Full Text] [Related]

  • 19. Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation.
    McLeod C, Fleeman N, Kirkham J, Bagust A, Boland A, Chu P, Dickson R, Dundar Y, Greenhalgh J, Modell B, Olujohungbe A, Telfer P, Walley T.
    Health Technol Assess; 2009 Jan 01; 13(1):iii-iv, ix-xi, 1-121. PubMed ID: 19068191
    [Abstract] [Full Text] [Related]

  • 20. Oral deferiprone for iron chelation in people with thalassaemia.
    Fisher SA, Brunskill SJ, Doree C, Chowdhury O, Gooding S, Roberts DJ.
    Cochrane Database Syst Rev; 2013 Aug 21; (8):CD004839. PubMed ID: 23966105
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.